Generate Biomedicines, Inc. Common Stock (GENB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Generate Biomedicines, Inc. Common Stock (GENB) has a cash flow conversion efficiency ratio of -0.127x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-57.94 Million) by net assets ($456.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View GENB stock price and chart for real-time trading data and today's change.
Generate Biomedicines, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Generate Biomedicines, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see GENB market cap overview for the company's overall valuation and market capitalisation.
Generate Biomedicines, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Generate Biomedicines, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see balance sheet size of Generate Biomedicines, Inc. Common Stock for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OFG Bancorp
NYSE:OFG
|
0.028x |
|
AbraSilver Resource Corp.
TO:ABRA
|
-0.603x |
|
SVG Optronics Co Ltd
SHE:300331
|
0.030x |
|
Shanghai Awinic Technology Co Ltd
SHG:688798
|
0.068x |
|
Jafron Biomedical Co Ltd
SHE:300529
|
0.010x |
|
Primaris Retail R.E. Invest. Tr. Units
TO:PMZ-UN
|
0.024x |
|
VIVENDI UNSPON.ARD EO 55
F:VVUD
|
N/A |
|
Motorcomm Electronic Technology Co. Ltd. A
SHG:688515
|
N/A |
Annual Cash Flow Conversion Efficiency for Generate Biomedicines, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Generate Biomedicines, Inc. Common Stock from 2024 to 2025. Review Generate Biomedicines, Inc. Common Stock (GENB) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-623.20 Million | $-200.62 Million | 0.322x | +18.95% |
| 2024-12-31 | $-435.09 Million | $-117.75 Million | 0.271x | -- |
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is … Read more